It's repeated every 3 years. The only FDA-approved version of this test is sold as Cologuard. Who Should Use At-Home Colon Cancer Tests? Guidelines from major medical groups in the U.S. say that ...

There's a new blood test to screen for colorectal cancer, but a new study found it's not as effective as a colonoscopy or ...

The cost is about $750. Neither the FIT nor the Cologuard test are as accurate at detecting polyps as the colonoscopy, the ...

The FDA has approved the Cologuard Plus test for colorectal cancer screening in adults aged 45 years at average risk for colorectal cancer. The Food and Drug Administration (FDA) has approved the ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Key Takeaways Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook.CEO Kevin Conroy ...

Cologuard is an at-home colon cancer screening kit that detects changes in genetic material indicating potential cancer or polyps. Medicare covers one kit per year under Original Medicare (Parts A and ...

Enter Cologuard, the at-home colon cancer screening test for people aged 45 and older. Perhaps best known by audiences for its cheeky approach to advertising, the Exact Sciences brand recently ...

Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based genomic profiling platform with widespread use in breast ...

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the firm's quarterly execution and forecast don't reflect its full potential.